Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 1/20 | 0.47 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.47 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.47 |
| ▸ | BRD7 | Q9NPI1 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | FNTA | P49354 | 1/20 | 0.44 |
| ▸ | FNTB | P49356 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 4/20 | 0.43 |
| ▸ | CA1 | P00915 | 4/20 | 0.43 |
| ▸ | CA2 | P00918 | 4/20 | 0.43 |
| ▸ | CA9 | Q16790 | 4/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNG | P07510 | 1/20 | 0.43 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30545233 | 1.00 | ENPP3 (0.47) | ENPP3ENPP1BRD9BRD7CYP2A6 | |
| Phosphine SCHEMBL28240948 | 0.98 | ENPP3 (0.46) | ENPP3ENPP1BRD9BRD7CYP2A6 | |
| SCHEMBL27454841 | 0.89 | CA12 (0.45) | ENPP3ENPP1CYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL25788028 | 0.87 | ENPP3 (0.42) | ENPP3ENPP1BRD9BRD7CYP2A6 | |
| SCHEMBL3357709 | 0.87 | ALDH1A1 (0.47) | ENPP3ENPP1CYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL15856458 | 0.87 | ENPP3 (0.42) | ENPP3ENPP1BRD9BRD7CYP2A6 | |
| SCHEMBL22515944 | 0.87 | ENPP3 (0.42) | ENPP3ENPP1BRD9BRD7CYP2A6 | |
| SCHEMBL4323024 | 0.86 | ENPP1 (0.48) | ENPP3ENPP1CYP2A6CYP1A2ALDH1A1 | |
| SCHEMBL26214138 | 0.85 | DHFR (0.45) | ENPP3ENPP1BRD9BRD7CYP2A6 | |
| SCHEMBL29866205 | 0.84 | CA12 (0.50) | ENPP3ENPP1CYP2A6CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260060932-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA LP (US) | 2026-03-05 | — | — | US | disclosed |
| US-20240238207-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA LP (US) | 2024-07-18 | — | — | US | disclosed |
| US-11911512-B2 | Encased tamper resistant controlled release dosage forms | PURDUE PHARMA L.P. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230301921-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA L.P. | 2023-09-28 | — | — | US | disclosed |
| CN-104873455-B | Coated Tamper Resistant Controlled Release Dosage Forms | 普渡制药公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11590082-B2 | Encased tamper resistant controlled release dosage forms | PURDUE PHARMA L.P. (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210251907-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA L.P. | 2021-08-19 | — | — | US | disclosed |
| US-10966932-B2 | Encased tamper resistant controlled release dosage forms | PURDUE PHARMA L.P. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200121608-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | PURDUE PHARMA LP (US) | 2020-04-23 | — | — | US | disclosed |
| US-20190022086-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | PURDUE PHARMA LP (US) | 2019-01-24 | — | — | US | disclosed |
| EP-1337244-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | Euroceltique S.A. (LU) | 2003-08-27 | — | — | EP | disclosed |
| CN-1407884-A | Controlled release hydrocodone formulations | EURO CELTIQUE SA (LU) | 2003-04-02 | — | — | CN | disclosed |
| US-20020192277-A1 | Controlled release hydrocodone formulations | PURDUE PHARMA L.P. | 2002-12-19 | — | — | US | disclosed |
| EP-1227798-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | Euro-Celtique S.A. (LU) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002036099-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | EURO-CELTIQUE S.A. (LU) | 2002-05-10 | — | — | WO | disclosed |
| WO-2000018378-A9 | SUSTAINED RELEASE HYDROMORPHONE FORMULATIONS EXHIBITING BIMODAL CHARACTERISTICS | EURO CELTIQUE SA (LU) | 2001-07-19 | — | — | WO | disclosed |
| WO-2001032148-A1 | CONTROLLED RELEASE HYDROCODONE FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 2001-05-10 | — | — | WO | disclosed |
| WO-2000018378-A1 | SUSTAINED RELEASE HYDROMORPHONE FORMULATIONS EXHIBITING BIMODAL CHARACTERISTICS | EURO-CELTIQUE, S.A. (LU) | 2000-04-06 | — | — | WO | disclosed |
| US-5668121-A | Glutamate (NMDA) receptor antagonists | WARNER-LAMBERT COMPANY (US) | 1997-09-16 | — | — | US | disclosed |
| US-5489717-A | Glutamate (NMDA) receptor antagonists | WARNER-LAMBERT COMPANY | 1996-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060932-A1 | Encased Tamper Resistant Controlled Release Dosage Forms | OGFR, OPRM1, OPRK1 | ENPP3 3354/4885ENPP1 3594/4885BRD9 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.